Freelite®


and Hevylite® Freelite & Hevylite for Monitoring


In the bone marrow of a multiple myeloma patient there will be clones producing:


(a) Intact Immunoglobulins only (b) Free Light Chains only


(c) Intact Immunoglobulins and Free Light Chains (FLCs)


Freelite and Hevylite measure independent biomarkers in multiple myeloma:


The International Myeloma Working Group recommend Freelite for the quantitative monitoring of patients with oligosecretory plasma cell disorders, including patients with AL amyloidosis, oligosecretory myeloma, and in nearly two-thirds of patients previously classified as having Non Secretory multiple myeloma.1


Additionally the International


Myeloma Working Group recommend monitoring Intact Immunoglobulin multiple myeloma patients periodically to identify light chain escape.


Use Freelite to quantitatively monitor patients with B cell dyscrasias


• FLC have a short serum half-life (2-6 hours) which shows response to treatment faster than intact immunoglobulin measurements (half-life 20 days) 38-41


Freelite


measures free light chains (mg/L)


Use together for optimal management of Myeloma patient care


Hevylite


measures intact immunoglobulins (g/L)


• Freelite is a more reliable and sensitive test than urine analysis.1


• Improve patient outcome with early detection of light chain escape.1,42,43


Freelite & Hevylite together provide the best monitoring solution for the management of multiple myeloma patients


Monoclonal protein obvious


>10g/L <10g/L


Monoclonal protein difficult to measure


Free Light Chains only Abnormal


Freelite ratio


Hevylite overcomes the difficult measurement of IgA monoclonal proteins


Measuring IgA monoclonal proteins that co-migrate in the region on SPE (serum protein electrophoresis) is often complex to interpret, making it difficult to monitor disease.


• In studies of more than 430 patients, 44% of IgA monoclonal  with Hevylite.44-49


• Detect more monoclonal protein during monitoring - detects 49% of samples vs. 19% using SPE.50,51


• Measure monoclonality even when total IgA is normal. Total IgA quantification doesn’t distinguish between monoclonal IgA and polyclonal IgA.


Monitor with Freelite plus Hevylite/SPE/ CZE


Monitor with Hevylite and Freelite


Monitor with Freelite


At Complete Response (CR) Measure Freelite ratio Measure Hevylite ratio Want to learn more?


To define a stringent CR


Residual Disease detection


Brioli et al. examine data from a study of over 600 intact Ig myeloma patients. Their analysis highlights the importance of monitoring with a free light chain assay, “to ensure that free light chain relapse is not missed”.


The International Myeloma Working Group state that the Hevylite assay is useful in patients with oligo-secretory disease and can overcome limitations associated with monitoring -migrating monoclonal IgA by electrophoresis.17


14


More information at: www.bindingsite.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28